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Abstract Secretin is the most potent regulator of pancreatic
bicarbonate, electrolyte and volume secretion. In this report, the
organization of the human secretin receptor (hSR) gene was
characterized by overlapping genomic phage clones. The hSR
gene consists of 13 exons and 12 introns with all the splice donor
and acceptor sites conforming to the canonical GT/AG rule. By
transient reporter gene assays, the wild-type promoter, contain-
ing 3.0 kb of the hSR gene 5P flanking region, was able to drive
5.8 þ 0.6 and 6.6 þ 0.2-fold (P6 0.01) increases in luciferase
activities in pancreatic ductule-derived PANC-1 and BPD-1
cells, respectively. By subsequent 5P and 3P deletion analysis, a
promoter element was identified within 3408 to 3158, relative to
the ATG codon. This promoter element was found to be cell-
specific since it could drive reporter gene expression in PANC-1
and BPD-1 cells but not in Hs 262.St, Hs 746T and KT3-1 cells.
The study of the transcriptional control of human secretin and its
receptor should shed light on the pathological developments of
pancreatic cancer and autism in the future.
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1. Introduction
Secretin was ¢rst discovered in 1902 by Bayliss and Starling
[1]. The primary action of secretin is to stimulate bicarbonate,
electrolyte and volume secretion from pancreatic ductule epi-
thelial cells. Other actions of secretin were reported including
inhibition of gastric emptying and acid output [2,3], stimula-
tion of hepatic bile £ow [4], stimulation of mucus, as well as
bicarbonate and epidermal growth factor secretion from duo-
denal Brunner’s glands [5]. The functions of secretin are medi-
ated via its speci¢c interactions with cell surface receptors.
Recently, cDNAs corresponding to rat [6] and human [7^9]
secretin receptors (SR) have been characterized. Similar to
other members in the same G protein-coupled receptor family,
the hSR contains a relatively large extracellular hydrophilic
domain. The importance of this N-terminal ectodomain in
ligand interaction was indicated by domain swapping experi-
ments [10] and by a novel approach using the recombinant
ectodomain to functionally antagonize the wild-type receptor
[11].
All members of the secretin-glucagon receptor family are
able to couple to Gs protein leading to the production of
intracellular cAMP. By using a protein kinase A (PKA) in-
hibitor, H-89, PKA was indicated to be largely responsible for
carrying out cellular responses upon secretin activation
[11,12]. Recently, termination of hSR signaling mechanism
was studied and it appeared that G protein-coupled receptor
kinase and phosphorylation-independent receptor internaliza-
tion are both important in receptor desensitization to protect
receptor-bearing cells from over-stimulation [12^15]. How-
ever, this acute desensitization event is reversible and is fol-
lowed by a rapid re-sensitization process [12].
The study of human secretin and its receptor has attracted
much more attention recently because of the possible treat-
ment of autistic patients with repeated intravenous infusion of
secretin [16]. This new potential therapeutic application of
secretin gives a totally new insight into the understanding of
this traditional hormone and its receptor. It is highly possible
that secretin is also a neuropeptide, and autism may be a
genetic defect involving mutation of the structure and/or pro-
moter of human secretin and/or secretin receptor genes. We
have previously mapped the gene to 2q14.1 by £uorescent in
situ hybridization [17], and now, we report here the genomic
organization and the functional characterization of 3 kb 5P
£anking region of the hSR gene.
2. Materials and methods
2.1. Genomic library screening
Two human genomic libraries, HL1067j (Clontech Laboratories,
Palo Alto, CA, USA) and LL02NS01 (ATCC, Rockville, MD,
USA), were screened with either probe A (1166 bp, 249^1414 bp of
the cDNA), probe B (427 bp, 108^534 bp of the cDNA), probe C (301
bp, 1^301 bp of the cDNA), probe D (137 bp, 1^137 bp of the cDNA)
or probe E (446 bp, 1254^1699 bp of the cDNA). Probes B, C and E
were obtained by polymerase chain reaction (PCR) ampli¢cation us-
ing primer pairs hSR5P (CGGGATCCAT GCGTCCCCAC
CTGTCGCCGC) and hSR3P (CGGATTTCCA GCTTCAGCAG
GTAGGAGTG), hSG5F (ACGAGGCCGG CCGGAGCCCG
GGACCCTGCG) and hSG5R (CTGGCACTGG CTGCTCCGTG
CCCAGGTCTC), or hSRG1 (GTGGTGGCCG TCCTCTACTG
CTTCCTCA) and hSRG2 (ACCCCTGAAC TTCTCTTCCC GAA-
GAG), respectively. The PCR typically contained 50 pmol primers,
200 WM dNTPs and 5 units Taq polymerase (Life Technologies, Inc.)
in the bu¡er provided by the manufacturer. The reaction times were
1 min at 94‡C, 58‡C and 72‡C, respectively, for 30 cycles. The PCR
fragments were subcloned into pBluescript SK (Stratagene, La Jolla,
CA, USA) for DNA sequence analysis using the T7 sequencing kit
(Pharmacia, Uppsala, Sweden). The probes were labeled using a Meg-
aprime DNA labeling kit and [K-32P]dATP (Amersham). Library
screening was performed essentially following the protocol described
earlier [7]. Phage DNA was puri¢ed by a Qiagen lambda phage kit
(Qiagen Inc., Santa Clarita, CA, USA) and subjected to restriction
mapping and DNA sequence analysis. DNA sequences of the positive
clones were analyzed by DNASIS v 3.6 (Hitachi, San Bruno, CA,
USA).
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 0 8 6 4 - 9
*Corresponding author. Fax: (852) 2857-4672.
E-mail: bkcc@hkusua.hku.hk
FEBS 22315 16-7-99
FEBS 22315 FEBS Letters 455 (1999) 209^214
2.2. Plasmid construction
A 3 kb restriction fragment (PstI) corresponding to the 5P upstream
region of hSR gene was subcloned into pBluescript KS (Stratagene)
to produce p42Ab. The expression plasmids p3039luc and p3039Rluc
were constructed by cloning the KpnI/SstI DNA fragment (33039 to
369 relative to ATG) into the luciferase reporter vector pGL2-Basic
(Promega, Madison, WI, USA) in forward and reverse orientations,
respectively. Other 5P and 3P deletion clones were obtained by releas-
ing restriction fragments from p3039luc. A nested family of 5P deletion
clones was generated from p681luc by exonuclease III/S1 nuclease
digestion (Pharmacia).
2.3. Cell culture and transient transfection
All cells including PANC-1 (human pancreatic ductule carcinoma,
ATCC) and BPD-1 (bovine pancreatic duct epithelium) were grown at
37‡C with 5% CO2 in DMEM supplemented with 10% fetal bovine
serum (FBS) and antibiotics (100 U/ml penicillin, 100 Wg/ml strepto-
mycin). For transient transfection assays, cells were seeded onto 6-well
plates (Costar 3506 San Diego, CA, USA) at a density of 1.5U105/
well. Transfection was performed 40 h later using a cocktail contain-
ing 1 Wg promoter-reporter construct, 0.5 Wg pSV-L-gal (Promega)
and 5 Wl LipofectAMINE reagent (Life Technologies, Inc.). Cells
were incubated for 7 h before the addition of 1 ml DMEM/20%
Fig. 1. Structure of the hSR gene. Positive clones obtained from library screenings were analyzed by DNA sequencing and restriction mapping.
BamHI (B) and SstI (S) restriction sites are indicated. Exons are represented as bars and the size (bp) of each exon is shown on the left. Clones
42, 4A, 5A, 8, 7, 6, 4, 2, 19A, 8-1 and G1 are arranged and overlapping to reveal the genomic organization of the hSR gene.
Table 1
Exon-intron splice junctions of the hSR gene
The positions at which introns interrupt the mRNA and protein sequences are indicated. Exon sequences are in capital letters. Introns were
partially sequenced, and the sizes were estimated by PCR and genomic and phage Southern blot analysis. The sizes of introns 8, 9, 10 and 12
were con¢rmed by DNA sequence analysis.
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FBS. Cell lysate was prepared 48 h later by washing the cells twice
with PBS followed by the addition of reporter lysis bu¡er (Promega).
Luciferase and galactosidase assays were performed essentially as de-
scribed earlier [18]. For each transfection study, luciferase activity was
determined and normalized based on the galactosidase activity. Plas-
mid DNA for transfection was prepared using the Qiagen Midi kit
(Qiagen).
3. Results and discussion
3.1. Genomic organization of the human secretin receptor
Ten overlapping and one non-overlapping phage clones
were obtained by screening the human genomic libraries
(probe A: clone 8-1; probe B: clones 2, 4, 6, 7, 8 and 19;
probe C: clones 4A and 5A; probe D: clone 42 and probe E:
G1) (Fig. 1). The overlapping region was 69.6 kb in length
which includes exons 1^11 and 10.4 kb 5P £anking region of
the gene. The 3P region of the gene was characterized by the
analysis of the non-overlapping clone G1 which spans exons
12 and 13. The minimal size of the gene was estimated to be
61 kb. The size of the intron between exons 11 and 12 is
probably above 2 kb since we were unable to produce a
PCR product using sequence-speci¢c primers for exons 11
and 12 in a genomic PCR ampli¢cation. In summary, the
hSR gene consists of 13 exons and 12 introns and spans
over 61 kb of genomic DNA. The sizes of the introns were
determined by PCR ampli¢cation coupled to agarose gel elec-
trophoresis and/or by restriction mapping of the overlapping
phage clones. The size of exons ranges from 42 bp (exon 12)
to 412 bp (exon 13), and that of introns ranges from below
1 kb to 13.6 kb (Table 1). A comparison of the hSR genomic
organization with that of other receptor genes in the same
family shows that the hSR is, as yet, the largest gene identi¢ed
[19^22]. The unusually large architecture of the hSR gene is
attributable to the sizes of the ¢rst (12.9 kb) and second (13.6
kb) introns. The exon-intron splice junctions of the hSR gene
agree with the canonical GT/AG rule [23] and all three types
of splice phasing were observed.
The genomic structures of human GIP, human VIP1, hu-
man and rat glucagon receptors [19^22] have been previously
described. With the exception that the rat glucagon receptor
gene has only 12 exons, all other receptor genes have 13
exons. The 11th exon/intron splice junction, which interrupts
the glutamine residue in human receptors, is absent in the rat
glucagon receptor gene. In addition, the exon-intron organi-
zations of all these genes in the secretin/glucagon family are
remarkably similar.
3.2. Analysis of the 5P £anking region of the hSR gene
The nucleotide sequence of 1.6 kb of the 5P £anking region
was determined (Fig. 2). No potential elements that are re-
quired for the accurate initiation of transcription, including
the TATA and CCAAT boxes, are evident within this region.
In fact, the absence of TATA and CCAAT motifs is not
unique to the hSR; other G protein-coupled receptor genes
such as the human K1b-adrenergic receptor and the growth
hormone-releasing hormone receptor [24,25] also lack these
sequence motifs in their promoters. A search of the 5P £anking
region sequence against the TFMATRIX revealed the pres-
ence of several transcription factor binding sites. Two Sp1
binding GC-rich motifs are found at 3205 and 3403. Sp1
sites have been frequently linked to transcriptional control
of genes that lack a functional TATA box. In addition, two
putative binding sites for the zinc ¢nger transcription factor
GATA are found at 3818 and 31536. Recent ¢ndings have
shown that GATA is expressed at high levels in the pancreas
and gut-derived cells [26,27]. In addition, there are two oc-
tamer sites for the homeobox domain factor Oct-1 at 31261
and 31598 and a binding site for CREB (cAMP-response
element binding protein) at 3642. All these motifs may con-
tribute cooperatively to the hormonal and developmental reg-
ulation as well as the basal expression of the hSR gene in
various tissues.
3.3. Initial mapping of the hSR gene promoter element to a
region from 3681 to 369
To localize the region essential for hSR gene expression,
several 5P and 3P deletion plasmids were constructed by link-
ing restriction fragments to the luciferase reporter gene. The
transcriptional activities of these promoter-luciferase con-
structs were tested by transfecting the plasmid individually
into PANC-1 (human pancreatic ductule carcinoma) and
BPD-1 (bovine pancreatic duct epithelium) cells (Fig. 3). It
was found that 3 kb of the hSR gene 5P £anking region
(Fig. 3: p3039luc) was capable of directing signi¢cant
(P6 0.01, ANOVA) increases in luciferase activities in both
PANC-1 (5.8-fold) and BPD-1 cells (6.6-fold), when com-
pared with the promoterless control, pGL2-basic. Subsequent
Fig. 2. Nucleotide sequence of the 5P £anking region of the hSR
gene. Bases relative to the ATG translation initiation codon (in
boldface, designated +1) are numbered on the left. The amino acid
sequence is shown below the nucleotide sequence. Consensus Oct-1,
GATA, CREB and Sp1 sequences are indicated and underlined.
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5P deletion constructs, p1430luc and p681luc, also supported
transcription of the reporter gene to approximately the same
extent in both cell lines suggesting that the 5P boundary of the
promoter resides within 681 bp from the translation start site.
On the other hand, low levels of luciferase activities were
observed in the 3P deletion clones p3039/681luc and p3039/
1430luc (Fig. 3), again indicating the importance of the se-
quences within the region from 3681 to 369. Two other
constructs, p3039Rluc and p681Rluc, with the putative pro-
moter regions in reverse orientation showed similar luciferase
activities when compared with the promoterless control,
pGL2-basic (Fig. 3). These results con¢rmed the nature of
this DNA fragment (3681/369) as a promoter element since
it functions in an orientation-dependent manner. In summary,
we have identi¢ed a functional promoter element residing in
the region from 3681 to 369 within the 5P £anking region of
the hSR gene.
3.4. Fine Mapping of the hSR promoter element to a region
within 3355 to 3158
In order to precisely map the location of the promoter
element within the region 3681 to 369, a number of progres-
sive 5P deletion clones were generated using the exonuclease
III/S1 nuclease nested deletion method [28]. The abilities of
these deletion clones to drive luciferase expression were again
tested by transient transfection into PANC-1 and BPD-1 cells
(Fig. 4). In PANC-1 cells, similar luciferase levels (P6 0.05,
ANOVA) were observed in p681luc (4.7-fold), p505luc (5.0-
fold), p470luc (5.7-fold), p408luc (4.8-fold) and p355luc (4.3-
fold). However, a further deletion of 61 bp (p294luc, 2.9-fold)
Fig. 3. Initial mapping of the hSR gene promoter element within 3681 to 369 in PANC-1 and BPD-1 cells. A: Restriction map of the hSR
gene 5P £anking region and schematic diagrams of various promoter-luciferase constructs. In transient expression assays, these constructs were
cotransfected with pSV-L-gal into (B) PANC-1 and (C) BPD-1 cells. Luciferase values are normalized by L-galactosidase expression and are
shown as the fold changes in relative promoter activities compared with that in the promoterless control pGL2-Basic. Values reported in the
¢gure represent the mean þ S.E.M. of six independent transfection experiments. Bars bearing ‘*’ (P6 0.05) and ‘**’ (P6 0.01) are statistically
di¡erent.
Fig. 4. Fine mapping of the hSR gene promoter element in PANC-1 and BPD-1 cells. A: A nested family of 5P deletion clones was generated
by ExoIII/S1 nuclease digestion. In transient expression assays, these constructs were cotransfected with pSV-L-gal into (B) PANC-1 and (C)
BPD-1 cells. Luciferase values are normalized by L-galactosidase expression and are shown as the fold changes in relative promoter activities
compared with that in the promoterless control pGL2-Basic. Values reported in the ¢gure represent the mean þ S.E.M. of six independent trans-
fection experiments. Bars bearing ‘*’ (P6 0.05) and ‘**’ (P6 0.01) are statistically di¡erent.
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and 197 bp (p158luc, 1.5-fold) from the 5P end of p355luc
caused drastic reductions (33% and 65%, respectively) in pro-
moter activities. Our data indicated that, in PANC-1 cells, the
5P boundary of the promoter element is located within 3355
to 3294. In addition, the 3P deletion clone (p411/158luc, 3411
to 3158) showed a high level of luciferase activity (6.6-fold),
suggesting that the proximal 154 bp upstream from the start
codon does not contain the 3P boundary of the promoter. In
summary, our data indicated that the region from 3355 to
3158 (197 bp) is su⁄cient as a promoter element to drive
expression in PANC-1 cells. By searching the sequences
against a database containing all the known cis-acting motifs
(http ://pdap1.trc.rwcp.or.jp/research/db/TFSEARCH.html),
only a consensus Sp1 site at 3205 is identi¢ed within this
region. It is highly possible that other novel transcription
factors are needed for the transcriptional regulation of the
hSR gene.
Although the overall expression pro¢les of the deletion
clones are similar in PANC-1 and BPD-1 cells (Figs. 3 and
4), there are some minor but interesting di¡erences. The se-
quences between 3355 to 3294 were important only in
PANC-1 cells since deletion of this region led to a 33% reduc-
tion in promoter function in PANC-1 cells but had no e¡ect
in BPD-1 cells (Fig. 4: PANC-1: 4.3-fold and 2.9-fold;
BPD1: 4.8-fold and 5.1-fold). On the contrary, the region
between 3408 to 3355 was only functional in BPD-1 cells.
In this cell line, there was a 40% drop (Fig. 4C, 7.9-fold to
4.8-fold) in promoter activity when this region of the pro-
moter was deleted. In summary, our data suggest the presence
of at least two distinct regions within the promoter. The prox-
imal region from 3294 to 3158 is probably responsible for
basal promoter functions and it appears that there was a
di¡erential use of upstream activator regions, 3355/3294
and 3408/3355, for transcription initiation in PANC-1 and
BPD-1 cells, respectively.
3.5. Cell speci¢city of the hSR promoter element
Five mammalian cell lines, PANC-1, BPD-1, Hs 262.St
(human stomach ¢broblast-like), Hs 746T (human stomach
carcinoma) and KT3-1 (mouse gonadotropes) were used to
study the cell speci¢city of the hSR promoter element. All
constructs with promoter sequences in the forward orientation
were capable of driving the luciferase expression in PANC-1
and BPD-1 cells at levels signi¢cantly above that of other cells
(P6 0.001, ANOVA) (Fig. 5). The same DNA sequences
drove negligible luciferase expression in Hs 262.St and Hs
746T cells, but interestingly, as indicated by constructs
p3039luc and p355luc, the hSR promoter is a weak promoter
in KT3-1 cells (P6 0.05, ANOVA). The signi¢cance of this
¢nding remains to be investigated.
Recently, the public have shown much interest in the pos-
sible treatment of autistic patients with secretin. It was re-
ported that autism is linked to biological and neurological
di¡erences in the brain. For instance, the disorder is related
to abnormalities in the structure of the brain such as di¡er-
ences in the size and the number of Purkinje cells within the
cerebellum. In addition, it has also been suggested that autism
is a genetic disorder [29]. The study of the regulation of hu-
man secretin and secretin receptor may provide a new window
to investigate the genetic aspects of autism and to provide a
better understanding of the pathophysiology of this receptor.
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